Cat. No.: HY-103173

Copy Link Print Information

5'-N-Ethylcarboxamidoadenosine

(Synonyms: NECA)

8 Cited Publications

Customer Review

Based on 8 publication(s) in Google Scholar

5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective adenosine receptor agonist.

For research use only. We do not sell to patients.

Purity: 99.09%
CAS No.: 35920-39-9
Formula: C₁₂H₁₆N₆O₄
Molecular Weight:308.29

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

5'-N-Ethylcarboxamidoadenosine Chemical Structure

CAS No.: 35920-39-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
Chemical Information
Publications (8)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective adenosine receptor agonist.

IC₅₀ & Target

Adenosine receptor^[1]

All Adenosine Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	2.4 μM Compound: NECA	Receptor stimulated adenylyl cyclase activity in CHO cells expressing human recombinant Adenosine A2B receptor Receptor stimulated adenylyl cyclase activity in CHO cells expressing human recombinant Adenosine A2B receptor	[PMID: 11459663]
CHO	EC₅₀	0.04 μM Compound: NECA	G-protein activation in human Adenosine A2A receptor expressing CHO cells using cAMP assay G-protein activation in human Adenosine A2A receptor expressing CHO cells using cAMP assay	[PMID: 11784146]
CHO	EC₅₀	84.8 nM Compound: NECA	Effective concentration for stimulation of [35S]GTP-gamma-S, binding at human adenosine A3 receptor expressed in CHO cells Effective concentration for stimulation of [35S]GTP-gamma-S, binding at human adenosine A3 receptor expressed in CHO cells	[PMID: 15214785]
CHO	EC₅₀	104 nM Compound: NECA	Agonistic activity against human adenosine A2B receptor expressed in CHO cells Agonistic activity against human adenosine A2B receptor expressed in CHO cells	[PMID: 15239649]
CHO	EC₅₀	440 nM Compound: NECA	Potency against cAMP formation in CHO cells expressing recombinant human A2B receptor Potency against cAMP formation in CHO cells expressing recombinant human A2B receptor	[PMID: 15267242]
CHO	EC₅₀	50 nM Compound: NECA	Potency against cAMP formation in CHO cells expressing recombinant human A2A receptor Potency against cAMP formation in CHO cells expressing recombinant human A2A receptor	[PMID: 15267242]
CHO	EC₅₀	160 nM Compound: 1, NECA	Activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of cAMP levels Activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of cAMP levels	[PMID: 17228880]
CHO	EC₅₀	155 nM Compound: NECA	Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of cAMP production Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of cAMP production	[PMID: 17306548]
CHO	EC₅₀	21.9 nM Compound: 2, NECA	Agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as stimulation of cAMP production Agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as stimulation of cAMP production	[PMID: 17378544]
CHO	EC₅₀	30 nM Compound: NECA	Agonist activity at human adenosine A1 receptor expressed in CHO cells by GTPPgammaS binding assay Agonist activity at human adenosine A1 receptor expressed in CHO cells by GTPPgammaS binding assay	[PMID: 20031406]
CHO	EC₅₀	38 nM Compound: NECA	Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as effect on cAMP production by luciferase reporter gene assay Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as effect on cAMP production by luciferase reporter gene assay	[PMID: 20031406]
CHO	EC₅₀	63 nM Compound: NECA	Agonist activity at human adenosine A3 receptor expressed in CHO cells by GTPPgammaS binding assay Agonist activity at human adenosine A3 receptor expressed in CHO cells by GTPPgammaS binding assay	[PMID: 20031406]
CHO	EC₅₀	10.2 nM Compound: NECA	Agonist activity at human recombinant adenosine receptor-1 expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production preincubated for 45 mins prior forskolin-induction measured after 15 mins by immunoassay Agonist activity at human recombinant adenosine receptor-1 expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production preincubated for 45 mins prior forskolin-induction measured after 15 mins by immunoassay	[PMID: 21858244]
CHO	EC₅₀	0.018 μM Compound: 2 (NECA)	Agonist activity at human recombinant adenosine A2A receptor expressed in CHO cells assessed as [3H]cAMP accumulation after 15 mins by liquid scintillation counting Agonist activity at human recombinant adenosine A2A receptor expressed in CHO cells assessed as [3H]cAMP accumulation after 15 mins by liquid scintillation counting	[PMID: 23245803]
CHO	EC₅₀	12.58 nM Compound: 1b, NECA	Agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as stimulation of [3H]cAMP levels by scintillation counting method Agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as stimulation of [3H]cAMP levels by scintillation counting method	[PMID: 25780876]
CHO	EC₅₀	>10000 nM Compound: 1b, NECA	Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of [3H]cAMP levels by scintillation counting method Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of [3H]cAMP levels by scintillation counting method	[PMID: 25780876]
CHO	EC₅₀	45 nM Compound: NECA	Agonist activity at human recombinant adenosine A2A receptor expressed in CHO cells assessed as stimulation of NECA-mediated cAMP accumulation preincubated for 15 mins followed by NECA addition measured after 15 mins by enzyme immunoassay Agonist activity at human recombinant adenosine A2A receptor expressed in CHO cells assessed as stimulation of NECA-mediated cAMP accumulation preincubated for 15 mins followed by NECA addition measured after 15 mins by enzyme immunoassay	10.1039/C5MD00086F
CHO-K1	EC₅₀	17.6 nM Compound: 2, NECA	Agonist activity at human adenosine A2A receptor expressed in CHO-K1 cells by cAMP accumulation assay Agonist activity at human adenosine A2A receptor expressed in CHO-K1 cells by cAMP accumulation assay	[PMID: 24900277]
COS-7	EC₅₀	0.078 μM Compound: NECA	Activity against human wild type adenosine A3 receptor expressed in COS7 cells as measured by accumulation of inositol phosphate by PLC assay Activity against human wild type adenosine A3 receptor expressed in COS7 cells as measured by accumulation of inositol phosphate by PLC assay	[PMID: 16640329]
COS-7	EC₅₀	10.4 μM Compound: NECA	Activity against human adenosine A3 receptor H272E mutant expressed in COS7 cells as measured by accumulation of inositol phosphate by PLC assay Activity against human adenosine A3 receptor H272E mutant expressed in COS7 cells as measured by accumulation of inositol phosphate by PLC assay	[PMID: 16640329]
HCT-116	IC₅₀	>10 μM Compound: NECA	Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay	[PMID: 35707146]
HEK293	IC₅₀	3.7 x 10^-8 M Compound: NECA	Displacement of [3H]CGS 21680 from human recombinant adenosine A2a receptor expressed in HEK293 cells Displacement of [3H]CGS 21680 from human recombinant adenosine A2a receptor expressed in HEK293 cells	[PMID: 26988801]
HEK293	IC₅₀	3.7 x 10^-8 M Compound: NECA	Displacement of [3H]CGS 21680 from human recombinant adenosine receptor A2A expressed in HEK293 cells measured after 120 mins by scintillation counting method Displacement of [3H]CGS 21680 from human recombinant adenosine receptor A2A expressed in HEK293 cells measured after 120 mins by scintillation counting method	[PMID: 27876250]
HEK293	IC₅₀	3.7 x 10^-2 μM Compound: NECA	Displacement of [3H]CGS 21680 from human recombinant adenosine receptor A2A expressed in HEK293 cells measured after 120 mins by scintillation counting method Displacement of [3H]CGS 21680 from human recombinant adenosine receptor A2A expressed in HEK293 cells measured after 120 mins by scintillation counting method	[PMID: 27876250]
HEK293	EC₅₀	188 nM Compound: 37; NECA	Partial agonist activity at recombinant mouse A3AR expressed in HEK293 cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 2 hrs in presence of A2BAR blocker PSB-603 by liquid scintillation counting analysis Partial agonist activity at recombinant mouse A3AR expressed in HEK293 cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 2 hrs in presence of A2BAR blocker PSB-603 by liquid scintillation counting analysis	[PMID: 32271569]
PBMC	IC₅₀	187 nM Compound: NECA	Antiinflammatory activity in rat PBMC assessed as inhibition of LPS-induced TNFalpha production after 20 hrs by ELISA Antiinflammatory activity in rat PBMC assessed as inhibition of LPS-induced TNFalpha production after 20 hrs by ELISA	[PMID: 20031406]
PBMC	IC₅₀	40 nM Compound: NECA	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 20 hrs by ELISA Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 20 hrs by ELISA	[PMID: 20031406]
PC-12	EC₅₀	130 nM Compound: 1	Potency against PC12 cell A2 adenosine receptor by adenylate cyclase activation Potency against PC12 cell A2 adenosine receptor by adenylate cyclase activation	[PMID: 3018244]
PC-3	IC₅₀	>10 μM Compound: NECA	Cytotoxicity against human PC-3 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay	[PMID: 35707146]
WI-38	IC₅₀	>10 μM Compound: NECA	Cytotoxicity against human WI-38 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as cell viability incubated for 72 to 96 hrs by MTT assay	[PMID: 35707146]

In Vivo

After the administration of 5'-N-Ethylcarboxamidoadenosine (NECA), the mean number of cocaine infusions obtained per session is decreased significantly in a dose-dependent manner [5'-N-Ethylcarboxamidoadenosine (NECA): F(4,12)=14.9; P<0.001]. The administration of 5'-N-Ethylcarboxamidoadenosine (NECA) [F(4,12)=16.1; P<0.001] results in a significant increase in latencies above values obtained for vehicle treatment^[1]. Daily i.p. injection of 5'-N-Ethylcarboxamidoadenosine (NECA) at 0.3 mg/kg/day for two weeks reduces malondialdehyde (MDA) levels in diabetic rats, but does not affect control rats. Daily treatment with NECA (0.3 mg/kg/day, i.p. for two weeks) reduces diabetes-induced gene expression of tumor necrosis factor (TNF)-α and interleukin (IL)-18 in diabetic rats, but does not affect control rats. Daily i.p. injection of 5'-N-Ethylcarboxamidoadenosine (NECA) at 0.3 mg/kg/day for two weeks also blocks the activation of JNK MAPK in diabetic rats, but does not affect control rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 35920-39-9
Appearance Solid
Molecular Weight 308.29
Formula C₁₂H₁₆N₆O₄
Color White to off-white
SMILES

O[C@H]1[C@H](N2C=NC3=C(N)N=CN=C23)O[C@H](C(NCC)=O)[C@H]1O
Synonyms

NECA
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All RT-PCRWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Nat Commun

Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs. [Abstract]

2026 Mar 31;17(1):3045. PMID: 41916982
Cell Death Dis

CD73 promotes tumor metastasis by modulating RICS/RhoA signaling and EMT in gastric cancer. [Abstract]

2020 Mar 23;11(3):202. PMID: 32205841

5'-N-Ethylcarboxamidoadenosine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Mar 23;11(3):202. [Abstract]

OT-I cytotoxic T lymphocytes and MC38-OVA were cocultured with 5'-N-Ethylcarboxamidoadenosine (NECA) (1 μM; 48 h). 5'-N-Ethylcarboxamidoadenosine (NECA), a potent immunosuppressive ligand, notably impaired the effect that OT-I CTLs killed MC38-OVA cancer cells.

5'-N-Ethylcarboxamidoadenosine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Mar 23;11(3):202. [Abstract]

Human Jurkat T cells were stimulated with 20 ng/mL PMA and 1 μg/mL ionomycin (IONO) in the presence of 5'-N-Ethylcarboxamidoadenosine (NECA) (1 μM) for 5 h with varied concentrations of compound 7ai (0.1, 1,10 μM). The gene expression of PD-1 and TIM-3 were determined by Q-PCR and standardized using GAPDH as an internal reference.
J Med Chem

Subtle Structural Changes across the Boundary between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-Based Derivatives. [Abstract]

2024 Mar 28;67(6):5075-5092. PMID: 38483150

5'-N-Ethylcarboxamidoadenosine purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Mar 28;67(6):5075-5092. [Abstract]

WB analysis of inhibition effects of CD73 plasmids, 5'-N-Ethylcarboxamidoadenosine (NECA) (10 μM), or adenosine in RhoA/LIMK/cofilin signaling. 5'-N-Ethylcarboxamidoadenosine (NECA) inhibited the phosphorylation of RhoA-LIMK-cofilin signaling and showed the reduction of p-LIMK and p-cofilin to the maximum extent in AGS cells.
J Med Chem

Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy. [Abstract]

2023 Apr 13;66(7):4734-4754. PMID: 36951370

5'-N-Ethylcarboxamidoadenosine purchased from MedChemExpress. Usage Cited in: J Med Chem. 2023 Apr 13;66(7):4734-4754. [Abstract]

5'-N-Ethylcarboxamidoadenosine (NECA) (1 μM) treatment significantly down-regulated the gene expressions of GZMB, IFNG, and IL-2 in Jurkat T cells.

5'-N-Ethylcarboxamidoadenosine purchased from MedChemExpress. Usage Cited in: J Med Chem. 2023 Apr 13;66(7):4734-4754. [Abstract]

Cytotoxic T lymphocytes from OT-I mouse splenocyte (OT-I CTL) were co-incubated with MC38-OVA cells for 48 h in the presence of 5'-N-Ethylcarboxamidoadenosine (NECA) (1 μM) with or without compound 38. Then, living MC38-OVA cells were stained with a cell-permeant dye Calcein AM with green fluorescence. 5'-N-Ethylcarboxamidoadenosine (NECA) profoundly impaired the cytotoxic function of OT-ICTL.
J Med Chem

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8 H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy. [Abstract]

2022 Mar 10;65(5):4367-4386. PMID: 35212542
Pharmaceutics

Effective Actions of Ion Release from Mesoporous Bioactive Glass and Macrophage Mediators on the Differentiation of Osteoprogenitor and Endothelial Progenitor Cells. [Abstract]

2021 Jul 27;13(8):1152. PMID: 34452110
Nanomaterials

Effects of Ipriflavone-Loaded Mesoporous Nanospheres on the Differentiation of Endothelial Progenitor Cells and Their Modulation by Macrophages. [Abstract]

2021 Apr 24;11(5):1102. PMID: 33923311
bioRxiv

2026 Mar 30.

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL (202.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2437 mL

16.2185 mL

32.4370 mL

5 mM

0.6487 mL

3.2437 mL

6.4874 mL

10 mM

0.3244 mL

1.6218 mL

3.2437 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Animal Administration^[1]

Male Wistar rats are used in this experiment. These animals range in weight between 350 and 425 g. They are housed individually in hanging wire cages under a 12-h light/dark cycle. The effects of 5'-N-Ethylcarboxamidoadenosine (NECA) are tested in four rats. In the experiment, either 5'-N-Ethylcarboxamidoadenosine (NECA) (5, 7.5, 10, 20 μg/kg) or vehicle (saline) is administered intraperitoneally 15 min prior to the start of test sessions. 5'-N-Ethylcarboxamidoadenosine (NECA) is administered following a random order crossover design. In most cases, animals are tested twice with the same dose^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Knapp CM, et al. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol Biochem Behav. 2001 Apr;68(4):797-803. [Content Brief]

[2]. Elsherbiny NM, et al. Reno-protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1. Eur Cytokine Netw. 2012 Jul-Sep;23(3):78-86. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2437 mL	16.2185 mL	32.4370 mL	81.0925 mL
	5 mM	0.6487 mL	3.2437 mL	6.4874 mL	16.2185 mL
	10 mM	0.3244 mL	1.6218 mL	3.2437 mL	8.1092 mL
	15 mM	0.2162 mL	1.0812 mL	2.1625 mL	5.4062 mL
	20 mM	0.1622 mL	0.8109 mL	1.6218 mL	4.0546 mL
	25 mM	0.1297 mL	0.6487 mL	1.2975 mL	3.2437 mL
	30 mM	0.1081 mL	0.5406 mL	1.0812 mL	2.7031 mL
	40 mM	0.0811 mL	0.4055 mL	0.8109 mL	2.0273 mL
	50 mM	0.0649 mL	0.3244 mL	0.6487 mL	1.6218 mL
	60 mM	0.0541 mL	0.2703 mL	0.5406 mL	1.3515 mL
	80 mM	0.0405 mL	0.2027 mL	0.4055 mL	1.0137 mL
	100 mM	0.0324 mL	0.1622 mL	0.3244 mL	0.8109 mL

Keywords

5'-N-Ethylcarboxamidoadenosine

8 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

5'-N-Ethylcarboxamidoadenosine

GPCR/G Protein Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-diabetic Compound Library

Neurotransmitter Receptor Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) 5'-N-Ethylcarboxamidoadenosine

All Adenosine Receptor Isoforms

Biological Activity

Chemical Information

Publications (8)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

5'-N-Ethylcarboxamidoadenosine

GPCR/G Protein Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-diabetic Compound Library

Neurotransmitter Receptor Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) 5'-N-Ethylcarboxamidoadenosine

All Adenosine Receptor Isoforms

Biological Activity

Chemical Information

Publications (8)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

5'-N-Ethylcarboxamidoadenosine Related Classifications

Cat. No.: HY-103173